Nkarta

$12.14 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Nkarta

Nkarta, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered natural killer (NK) and cell therapies to treat cancer. Its modular NK cell engineering platform allows it to generate new product candidates. The Company’s engineered CAR-NK cells generally consist of an NK cell engineered with a targeting receptor, OX40 costimulatory domain, CD3z signaling moiety, and mbIL-15. This platform is modular, which enables optimization of different ways to enhance the natural signaling of engineered cells, as well as the ability to attach and optimize new targeting receptors. The Company’s lead product candidates are NKX101 and NKX019. The Company’s NK cell engineering platform is designed for engineering T cells and NK cells and understanding of NK cell biology.

Stock Analysis

last close $12.14
1-mo return -5.1%
3-mo return -38.4%
avg daily vol. 438.21T
52-week high 58.78
52-week low 11.5
market cap. $400M
forward pe -
annual div. -
roe -26.8%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 78.4%
baraka

Subscribe now for daily local and international financial news

Subscribe